After Jeune Aesthetics, a wholly owned subsidiary of Krystal Biotech, announced interim safety and efficacy results from both Cohorts 3 and 4 of PEARL-1, a Phase 1 study evaluating KB301, an investigational aesthetic treatment designed to increase type III collagen levels in the skin, Stifel said the firm thinks today’s PEARL-1 study update is “further proof that delivery of genes to the skin using HSV-1 vectors goes beyond DEB,” or dystrophic epidermolysis bullosa, and “may also find its niche in a completely different market – aesthetics.” The firm, which thinks shares could see an incremental boost on today’s news as the update further validates “platform value” for the stock, reiterates a Buy rating on Krystal shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
- Krystal Biotech price target raised to $206 from $201 at Evercore ISI
- Krystal Biotech price target raised to $208 from $153 at Chardan
- Krystal Biotech downgraded to Neutral from Buy at Citi
- Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates